Komori
Immuno-Biological Laboratories (4570) · FactRestatedLatest Occurring Fact (2026-09-15): "Dropped"

End of LipoTEST’s New Customer Acquisition Activities and Sluggish Order Growth

First written in FY2017-Q3. 2 of 6 entries say "Restated". Latest entry: 2026-09-15.

6entries
10years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseWorsenedFY2017RestatedFY2020-Q1 – 2026-09-152017: 220172018: 020182019: 120192020: 120202021: 120212022: 020222023: 020232024: 020242025: 020252026: 12026
Same theme, other companies
Testing Services Business Using Small-Volume Blood Collection and Testing LaboratoriesA theme 2 companies write about · 1 as a headwind · 1 as a tailwind

0 other companies' latest entry also says "Dropped".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. 2026-09-15DroppedOccurring FactSuggests it is closing out

    「At a meeting of the Board of Directors held today, the Company resolved to end the provision of the testing services “LipoSEARCH®,” “LipoTEST,” and “LipoCULTURE” upon accepting orders through 31 March 2027, and hereby announces this decision.」

    Regarding LipoTEST, the Company moved from continuing to provide the service amid sluggish order growth to deciding to end provision with orders accepted through 31 March 2027.
  2. FY2021-Q3RestatedAnnual report

    「LipoTEST, the animal service, continued to generate solid sales, and the company aims to expand transactions through online seminars and other initiatives.」

    The solid sales of LipoTEST and the policy of expanding transactions through online seminars and other initiatives were reconfirmed.
  3. FY2021-Q1Solid sales and expansion through online seminarsAnnual report

    「LipoTEST, the animal service, continued to generate solid sales, and the company aims to expand transactions through online seminars and other initiatives.」

    LipoTEST generated solid sales, and the company disclosed a policy of expanding transactions through online seminars and other initiatives.
  4. FY2020-Q1RestatedAnnual report

    「Meanwhile, revenue from the animal service LipoTEST remained broadly in line with the previous year.」

    Although the company had previously disclosed the end of new-customer acquisition activities and the impact of competition on LipoTEST, revenue during the quarter was broadly in line with the previous year.
  5. FY2017WorsenedAnnual report

    「Revenue from LipoTEST®, a service measuring cholesterol and triglycerides in pets, declined due to competition from other companies.」

    In addition to sluggish orders following the end of new-customer acquisition activities, LipoTEST recorded lower revenue due to competition from other companies.
  6. FY2017-Q3First statedAnnual report

    「In addition, orders for LipoTEST, a diagnostic support service for companion animals at veterinary hospitals, remained sluggish partly because seminars and other activities to acquire new veterinary hospital customers had ended.」

    For LipoTEST, this was the first disclosure of the business result that orders remained sluggish after seminars and other activities aimed at acquiring new customers had ended.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet. It last moved in the Occurring Fact of 2026-09-15: "Dropped".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
End of LipoTEST’s New Customer Acquisition Activities and Sluggish Order Growth | Immuno-Biological Laboratories Co.,Ltd. (4570) | Komori